Global Hemophilia Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Hemophilia Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ‘Emicizumab’ by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ‘Eloctate’ for type A and ‘Aprolix’ for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action.
The global Hemophilia Drugs market size was US$ 12730 million in 2024 and is forecast to a readjusted size of US$ 16970 million by 2034 with a CAGR of 4.1% during the forecast period 2024-2034.
With increasing attention on prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market’s growth over the forecast period.
In terms of sales (consumption) side, this report focuses on the sales of Hemophilia Drugs by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Hemophilia Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Hemophilia Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.

Baxalta
Bayer
CSL Behring
Pfizer
Alnylam Pharmaceuticals
BioMarin
Catalyst Biosciences
Dimension Therapeutics
F. Hoffmann-La Roche
Grifols
Octapharma
Sangamo Biosciences
Spark Therapeutics
Swedish Orphan Biovitrum
By Type
Hemophilia A
Inhibitors
Hemophilia B
Von Willebrand Disease
By Application
Recombinant Therapies
Plasma-Derived Therapies
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Hemophilia Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Hemophilia Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hemophilia Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.
The global Hemophilia Drugs market size was US$ 12730 million in 2024 and is forecast to a readjusted size of US$ 16970 million by 2034 with a CAGR of 4.1% during the forecast period 2024-2034.
With increasing attention on prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market’s growth over the forecast period.
In terms of sales (consumption) side, this report focuses on the sales of Hemophilia Drugs by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Hemophilia Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Hemophilia Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.

By Company
Baxalta
Bayer
CSL Behring
Pfizer
Alnylam Pharmaceuticals
BioMarin
Catalyst Biosciences
Dimension Therapeutics
F. Hoffmann-La Roche
Grifols
Octapharma
Sangamo Biosciences
Spark Therapeutics
Swedish Orphan Biovitrum
By Type
Hemophilia A
Inhibitors
Hemophilia B
Von Willebrand Disease
By Application
Recombinant Therapies
Plasma-Derived Therapies
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Hemophilia Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Hemophilia Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hemophilia Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.
